Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Futura Medical ( (GB:FUM) ) has shared an update.
Futura Medical has confirmed that its total issued share capital stands at 581,327,755 ordinary shares, all of which carry voting rights as the company holds no shares in treasury. This updated share capital and voting rights figure provides a new denominator for investors assessing whether they must disclose holdings or changes in their stake under UK financial disclosure and transparency rules, reinforcing governance clarity and regulatory compliance for shareholders and market participants.
The most recent analyst rating on (GB:FUM) stock is a Buy with a £140.00 price target. To see the full list of analyst forecasts on Futura Medical stock, see the GB:FUM Stock Forecast page.
More about Futura Medical
Futura Medical plc is a UK-based pharmaceutical company specialising in innovative sexual health products, with a core focus on research, development and commercialisation of topically delivered gel formulations. Its lead product, Eroxon, is an over-the-counter topical gel for erectile dysfunction, complemented by pipeline candidates such as WSD4000 for impaired sexual response in women and Eroxon Intense, targeting significant unmet needs in both male and female sexual health across major consumer markets including the US and Europe through partners like Haleon and Cooper Consumer Health.
Average Trading Volume: 6,116,741
Technical Sentiment Signal: Sell
Current Market Cap: £6.39M
For detailed information about FUM stock, go to TipRanks’ Stock Analysis page.